Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 10:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 4,617 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Genital Diseases, Male Clear all
Recruiting Phase 1Phase 2 Interventional

A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer

NCT07567846
View directory record Official record
Conditions
Advanced Prostate Cancer, Metastatic Prostate Cancer
Interventions
GDC-1261
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Scottsdale, Arizona • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 15, 2026, 10:05 AM EDT
Enrolling by invitation Phase 1 Interventional

A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4

NCT07218003
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Cervical Cancer, Head and Neck Squamous Cell Cancer, Triple Negative Breast Cancer (TNBC), Urothelial Carcinoma Bladder, Gastroesophageal Junction (GEJ) Adenocarcinoma, Esophageal Squamous Cell Cancer, Gastric Cancer, Cancer, Solid Tumors (Phase 1)
Interventions
RNDO-564, Pembrolizumab
Drug
Lead sponsor
Rondo Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
11
States / cities
San Francisco, California • New Haven, Connecticut • Grand Rapids, Michigan + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 15, 2026, 10:05 AM EDT
Recruiting Phase 1 Interventional

Novel ACK1 Inhibitor (R)-9b in Patients With Prostate Cancer

NCT06705686
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer (CRPC), Metastatic Castration-resistant Prostate Carcinoma
Interventions
(R)-9bMS
Drug
Lead sponsor
TechnoGenesys, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 20, 2026 · Synced Oct 15, 2026, 10:05 AM EDT
Completed Phase 3 Interventional Results available

TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate Cancer

NCT04887506
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer, Metastatic Castration-sensitive Prostate Cancer, Metastatic Prostate Cancer
Interventions
TAVT-45, Zytiga, Prednisone
Drug
Lead sponsor
Tavanta Therapeutics
Industry
Eligibility
18 Years and older · Male only
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
13
States / cities
Homewood, Alabama • Tucson, Arizona • Little Rock, Arkansas + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2024 · Synced Oct 15, 2026, 10:05 AM EDT
Completed Not applicable Interventional

Rapid Molecular Organism Identification and Mixed Flora Antibiotic Resistance Profiling (MixAR) Prospective Study

NCT03931538
View directory record Official record
Conditions
Urinary Tract Infections, Prostatitis, Interstitial Cystitis
Interventions
Guidance 4.0 PCR test, Urine Culture
Diagnostic Test
Lead sponsor
Pathnostics
Industry
Eligibility
18 Years and older
Enrollment
2,511 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 28, 2023 · Synced Oct 15, 2026, 10:05 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

The Molecular Predisposition to Hereditary Nonpolyposis Colon Cancer (HNPCC)

NCT01447199
View directory record Official record
Conditions
Bladder Cancer, Colorectal Cancer, Endometrial Cancer, Kidney Cancer, Skin Cancer, Uterus Cancer
Interventions
Health and Diet Questionnaire
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1994 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 7, 2020 · Synced Oct 15, 2026, 10:05 AM EDT
Recruiting Phase 2 Interventional

PyL in Patients With High Risk and Biochemically Recurrent Prostate Cancer

NCT04700332
View directory record Official record
Conditions
Prostate Cancer
Interventions
DCFPyL PET/CT
Drug
Lead sponsor
Hoag Memorial Hospital Presbyterian
Other
Eligibility
18 Years and older · Male only
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Jul 27, 2021 · Synced Oct 15, 2026, 10:05 AM EDT
Completed Not applicable Interventional

Therapy for Erectile Dysfunction Adaptation of ACT for Compliance With an Erectile Rehabilitation Program

NCT01275404
View directory record Official record
Conditions
Prostate Cancer
Interventions
Sexual Medicine Rehabilitation Program + nurse practitioner information phone calls, Sexual Medicine Rehabilitation Program + Acceptance and Commitment Therapy for Erectile Dysfunction
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years and older · Male only
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 15, 2019 · Synced Oct 15, 2026, 10:05 AM EDT
Completed Not applicable Interventional

Vacuum Erection Device in Improving Recovery of Erectile Function in Patients With Prostate Cancer Undergoing Surgery

NCT01660152
View directory record Official record
Conditions
Male Erectile Disorder, Prostate Cancer, Sexual Dysfunction
Interventions
Sexual Health Inventory for Men (SHIM) questionnaire administration, management of therapy complications, Daily vacuum therapy
Other · Procedure
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
Up to 70 Years · Male only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 13, 2017 · Synced Oct 15, 2026, 10:05 AM EDT
Withdrawn Phase 2 Interventional

Botulinum Toxin Injection With Prostate Brachytherapy

NCT00681148
View directory record Official record
Conditions
Prostate Cancer, Lower Urinary Tract Symptoms, Radioactive Seed Implantation
Interventions
Botox injection, Saline injection
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 21, 2013 · Synced Oct 15, 2026, 10:05 AM EDT
Recruiting Phase 2Phase 3 Interventional

Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer

NCT04787744
View directory record Official record
Conditions
Prostate Cancer, Oligometastasis, Oligorecurrence, Recurrent Prostate Cancer, Metastatic Prostate Cancer, De Novo Prostate Cancer
Interventions
PET-directed Local Therapy using Surgery, PET-directed Local Therapy using Radiation, Salvage Local Therapy for locally recurrent disease, Goserelin, Histrelin, Leuprolide & Triptorelin, ADT + Nilutamide, Flutamide, & Bicalutamide, Degarelix & Relugolix, ADT + Docetaxel +/- prednisone, ADT + Abiraterone + Prednisone, ADT + Abiraterone + Methylprednisolone, ADT + Apalutamide, ADT + Enzalutamide, Prostate-directed Radiation for De novo oligometastatic prostate cancer
Procedure · Radiation · Other + 1 more
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older · Male only
Enrollment
464 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
20
States / cities
Long Beach, California • West Los Angeles, California • Washington D.C., District of Columbia + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 15, 2026, 10:05 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Comparison of Traditional and MOSES Laser Enucleation of the Prostate (MOLEP): A Prospective, Randomized, Double-blinded Control Trial A Comparison of Traditional and MOSES Laser Enucleation of the Prostate (MOLEP): A Prospective, Randomized, Double-blinded Control Trial

NCT04263987
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
Moses laser enucleation of prostate
Procedure
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
50 Years to 90 Years · Male only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 31, 2022 · Synced Oct 15, 2026, 10:05 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

The Compartmental Biology of HIV in the Male Genital Tract

NCT02638493
View directory record Official record
Conditions
Human Immunodeficiency Virus, Virus Shedding
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 60 Years · Male only
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 24, 2017 · Synced Oct 15, 2026, 10:05 AM EDT
Completed No phase listed Observational

Frequency of Prostate-Specific Antigen Screening in African American Men in the San Francisco Area

NCT00702104
View directory record Official record
Conditions
Prostate Cancer
Interventions
survey administration
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
35 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 14, 2013 · Synced Oct 15, 2026, 10:05 AM EDT
Active, not recruiting Phase 2 Interventional

Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors

NCT03836352
View directory record Official record
Conditions
Ovarian Cancer, Hepatocellular Carcinoma, Non-small Cell Lung Cancer, Bladder Cancer, Microsatellite Instability-High
Interventions
DPX-Survivac, Cyclophosphamide, Pembrolizumab
Other · Drug
Lead sponsor
ImmunoVaccine Technologies, Inc. (IMV Inc.)
Industry
Eligibility
18 Years and older
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
15
States / cities
Tucson, Arizona • Los Angeles, California • Boca Raton, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2022 · Synced Oct 15, 2026, 10:05 AM EDT
Active, not recruiting Phase 1 Interventional

Periprostatic Neurolysis in Prostate Cancer

NCT07100847
View directory record Official record
Conditions
PROSTATE CANCER, NERVES, NEUROBIOLOGY OF CANCER, NEUROLYSIS
Interventions
Periprostatic neurolysis with dehydrated alcohol (ethanol)
Procedure
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 15, 2026, 10:05 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Prostate Cancer Genius App Education and Home-based PSA Screening for African American Men

NCT05331638
View directory record Official record
Conditions
Prostate Cancer, Health Behavior
Interventions
Prostate Cancer Genius App, US Prevention Taskforce App
Behavioral
Lead sponsor
University of Oklahoma
Other
Eligibility
55 Years to 69 Years · Male only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 15, 2026, 10:05 AM EDT
Recruiting Phase 3 Interventional

A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)

NCT07723248
View directory record Official record
Conditions
Metastatic Castration Resistant Prostate Cancer
Interventions
Rinzimetostat, Darolutamide, Enzalutamide, Docetaxel
Drug
Lead sponsor
ORIC Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
11
States / cities
Coral Springs, Florida • Jeffersonville, Indiana • Holland, Michigan + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 15, 2026, 10:05 AM EDT
Withdrawn Phase 2 Interventional

Tadalafil for Treatment of Priapism in Men With Sickle Cell Anemia

NCT00538564
View directory record Official record
Conditions
Sickle Cell Anemia, Priapism
Interventions
tadalafil, placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 45 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 21, 2016 · Synced Oct 15, 2026, 10:05 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Decision Impact Trial of the ExoDx Prostate (IntelliScore)

NCT03235687
View directory record Official record
Conditions
Cancer of the Prostate
Interventions
ExoDx Prostate (IntelliScore)
Diagnostic Test
Lead sponsor
Exosome Diagnostics, Inc.
Industry
Eligibility
50 Years and older · Male only
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
1
States / cities
Towson, Maryland
Source: ClinicalTrials.gov public record
Updated May 6, 2022 · Synced Oct 15, 2026, 10:05 AM EDT
Terminated Phase 2 Interventional Results available

Pilot Study of PLX3397 in Patients With Advanced Castration-Resistant Prostate Cancer (CRPC)

NCT01499043
View directory record Official record
Conditions
Prostate Cancer
Interventions
PLX3397
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 4, 2020 · Synced Oct 15, 2026, 10:05 AM EDT
Completed Not applicable Interventional Results available

Effectiveness of Electronic Health Record-Based Interventions for Improving Follow-Up in Primary Care

NCT01346839
View directory record Official record
Conditions
Colon Cancer, Lung Cancer, Prostate Cancer
Interventions
Contact Intervention
Behavioral
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
1,256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Houston, Texas • Temple, Texas
Source: ClinicalTrials.gov public record
Updated Feb 9, 2016 · Synced Oct 15, 2026, 10:05 AM EDT
Terminated Early Phase 1 Interventional

Hydroxychloroquine in Blocking Autophagy in Patients With Prostate Cancer Undergoing Surgery or Active Surveillance

NCT02421575
View directory record Official record
Conditions
Prostate Carcinoma
Interventions
Hydroxychloroquine, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older · Male only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 2, 2017 · Synced Oct 15, 2026, 10:05 AM EDT
Recruiting Phase 1 Interventional

A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer

NCT06067841
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
BMS-986460
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older · Male only
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
8
States / cities
Palo Alto, California • Sarasota, Florida • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 15, 2026, 10:05 AM EDT